OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE127 in Autoimmune Diseases

OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases

Servier exercised first of two steps under OSE-127 global licensing option agreement OSE-127, an IL-7R antagonist, is currently in Phase 1 clinical testing Regulatory News: This press release feat...

More From BioPortfolio on "OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"